Cutting-edge cancer treatments: expense & expectation? CRUK, 23 February, 2012
Aim of the workshop – For delegates to understand the cost/benefits of new (and existing) technologies and treatments for cancer patients the public expectations of the NHS in providing cancer treatments and the importance of PPI in cancer research and services.
Impact of the workshop –For delegates to apply in their PPI work,an informed patient perspective on the costs/benefits of new (and existing) technologies and treatments for cancer patients in the current economic climate.
Programme
Introduction and clarification of aims of the workshop
Richard Stephens, Incoming Chair of CLG & ICPV Member
What do cancer patients want from the NHS? - Laura Thomas, Ipsos MORI
Stratified medicine – What is it and could it reduce costs in long term?
Dr Emily Shaw, Clinical Lead, Stratified Medicine Unit, Cancer Research UK
What is the role of chemoprevention & do we need to licence drugs for this use? What is the future for use of orphan drugs?
Professor Jack Cuzick, Wolfson Institute
Imaging in research and early drug development – role of ECMC What happened to the “Star Wand?”
Prof Kerry Chester UCL , Professor of Molecular Medicine, University College London
Supporting research, protecting patients: Cancer Research UK's recommendations to reform the Clinical Trials Directive (for report on the reform go to our resources page
Emma Greenwood, Policy Manager, CRUK
Delivering World Class Radiotherapy
Tim Cooper, Associate Director-Radiotherapy, National Cancer Action Team
New models of radiotherapy
Dr Jayant Vaidya, Breast Cancer Specialist, University College London
How do we achieve cost effective cancer treatments in the UK?
Prof Peter Littlejohns Kings College London & previously at NICE
Drug pricing issues - Rob Day, Head of Oncololgy, Pfizer
Relationships between the pharma industry and patients - Stuart Pritchard, GSK
Click here for speakers presentations, review of the day and images
News
Warwick Clinical Trials
Course
12 members of ICPV attended a residential
Clinical Trials Course at the University of Warwick from 17th to 19th April 2018. The course was run by Professor Janet Dunn and covered the different types of studies undertaken; consent; trial
design; statistics and bringing a drug to market. One of the highlights of the course was a visit to the West Midlands Surgical Training Centre where delegates had the privilege of seeing real body
parts and having basic anatomy explained to them by the team. The delegates would like to thank Professor Janet Dunn for her outstanding enthusiasm and for her generous
hospitality.
Open letter calling on Government to prioritise interests of cancer patients in Brexit negotiations
ICPV have come together with 18 other cancer charities to put our names to an open letter to Government. We want Government to prioritise seeking continued alignment with the EU drug licensing
process and Clinical Trials Regulation after Brexit. It is hoped this letter will be published in the national press in the near future.
See below to read.
2017 Summer School
The 2017 ICPV Summer School was held over two days in June at Stirling University. The theme of the event was Cancer Survivorship and Living Well Cancer. Click below for details of the course. More details.
VOICE 2016
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
eCancer Videos
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
UNITE2CURE
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
TRACERx
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.
Print 